On February 9, 2018 Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that the company is scheduled to present an update on the company’s programs and progress at several upcoming conferences (Press release, Trillium Therapeutics, FEB 9, 2018, View Source [SID1234523881]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Conferences:

Leerink Partners 7th Annual Global Healthcare Conference
Presenters: Dr. Niclas Stiernholm, Chief Executive Officer
Dr. Robert Uger, Chief Scientific Officer
Date and Time: Feb. 15, 2018 at 1:30 p.m. ET
Location: Lotte New York Palace Hotel, New York City
A live audio webcast of this presentation will be available under the investor relations section of Trillium’s website at www.trilliumtherapeutics.com. A replay of the presentation will be available following the event.

Cowen and Company 38th Annual Healthcare Conference
Presenters: Dr. Niclas Stiernholm, Chief Executive Officer
Dr. Robert Uger, Chief Scientific Officer
Date and Time: Mar. 14, 2018 at 8:00 a.m. ET
Location: The Boston Marriott Copley Place, Boston

Scientific Conference:

4th Annual ICI Boston
Presenter: Dr. Robert Uger, Chief Scientific Officer
Title: Targeting the CD47 "Do Not Eat" Signal with TTI-621 (SIRPa-IgG1 Fc)
Date and Time: Mar. 21, 2018 at 3:00 p.m. ET
Location: Revere Hotel Boston Common, Boston